Literature DB >> 3187293

Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis.

A de Forges1, A Rey, M Klink, M Ghosn, A Kramar, J P Droz.   

Abstract

In order to define the prognostic factors for metastatic renal carcinoma, we reviewed 134 patients who were treated from 1971 through 1986. Survival rates were 72, 45, and 25% at 6, 12, and 18 months, respectively. Seventeen variables were tested using the logrank test. Improved survival was correlated with normal performance status, and an absence of fever, weight loss, hepatic metastasis, and lung metastasis (or, if lung metastasis was present, less than 2 cm in diameter and limited to one site), a disease-free interval, sedimentation rate less than 100, and renal surgery. Four variables retained significant value in the multivariate analysis: hepatic metastasis, lung metastasis, disease-free interval, and a variable combining the sedimentation rate and the weight loss (SWRL). Predictive survival rates based on these variables were calculated from the Cox model. Six subgroups of patients were identified. The estimation of survival is clinically of value for future phase II trials of chemotherapy in patients with adult metastatic renal carcinoma.

Entities:  

Mesh:

Year:  1988        PMID: 3187293     DOI: 10.1002/ssu.2980040302

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  9 in total

1.  Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie.

Authors:  Sylvie Negrier; Frédéric Gomez; Jean-Yves Douillard; Alain Ravaud; Christine Chevreau; Murielle Buclon; David Perol; Christine Lasset; Bernard Escudier
Journal:  World J Urol       Date:  2005-02-12       Impact factor: 4.226

2.  Gemcitabine: a phase II study in patients with advanced renal cancer.

Authors:  P H De Mulder; L Weissbach; G Jakse; R Osieka; J Blatter
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

Review 3.  Predictive models for the practical management of renal cell carcinoma.

Authors:  Lui Shiong Lee; Min-Han Tan
Journal:  Nat Rev Urol       Date:  2012-01-10       Impact factor: 14.432

Review 4.  Prognostic factors of immunotherapy in metastatic renal cell carcinoma.

Authors:  Peeter Padrik
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

5.  A Nomogram Predicting the Prognosis of Renal Cell Carcinoma Patients with Lung Metastases.

Authors:  Xinyu Sheng; Xuan Lu; Jian Wu; Lu Chen; Hongcui Cao
Journal:  Biomed Res Int       Date:  2021-03-18       Impact factor: 3.411

6.  EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.

Authors:  P H De Mulder; G Oosterhof; C Bouffioux; A T van Oosterom; K Vermeylen; R Sylvester
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

Review 7.  Novel concepts in the staging of renal cell carcinoma.

Authors:  Dan Leibovici; Arie Lindner; Avishay Sella; Amnon Zisman
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 2.862

8.  A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma.

Authors:  Kang Su Cho; Young Deuk Choi; Se Joong Kim; Chun Il Kim; Byung Ha Chung; Do Hwan Seong; Dong Hyeon Lee; Jin Seon Cho; In Rae Cho; Sung Joon Hong
Journal:  Yonsei Med J       Date:  2008-06-30       Impact factor: 2.759

9.  Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients.

Authors:  T Philip; S Negrier; C Lasset; B Coronel; M Bret; J Y Blay; Y Merrouche; C Carrie; P Kaemmerlen; F Chauvin
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.